Matches in SemOpenAlex for { <https://semopenalex.org/work/W2914446712> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W2914446712 endingPage "3424" @default.
- W2914446712 startingPage "3424" @default.
- W2914446712 abstract "Abstract To reverse non-APL AML patients with post-transplantation relapse before hematological relapse(early-stage relapse), we investigated the safety and efficacy of a new epigenetic therapy(DNA methyltransferase inhibitors, Decitabine and histone deacetylase inhibitors, Chidamide, plus Thymalfasin simultaneously). Twenty-four patients were enrolled in this observational study. The most common adverse event was CTCAE grade 2 thrombocytopenia (20/24). No acute GVHD was observed in patients received this treatment regimen. Strikingly all 24 patients responded to this epigenetic therapy with minute residual disease(MRD) decreasing (ORR 100%). At the more than 3-year follow-up, overall survival rate is 87.5%(21/24), with relapse-free survival rate of 75%(18/24). With this epigenetic therapy for 3 months, Th1 cells and CD3+CD4-CD8+T cells increased gradually, and Th17 cells decreased. The status of Th1 and Th17 cells remained at the time of 3 months after discontinuation. Interestingly, the Th1/Th17 ratio was low in patients with relapse disease and then increased gradually during this treatment regimen, correlated with the down trend of MRD. Therefore, our new epigenetic therapy is safe and tolerable for non-APL AML suffering post-transplant early relapse. The polarization for Th1/Th17 and the significant elevated ratio of Th1/Th17 seemed to better reflect the epigenetic therapy-mediated immune effect, which maybe a good biomarker for the early relapse monitoring. Disclosures No relevant conflicts of interest to declare." @default.
- W2914446712 created "2019-02-21" @default.
- W2914446712 creator A5023205295 @default.
- W2914446712 creator A5030479246 @default.
- W2914446712 creator A5033694430 @default.
- W2914446712 creator A5040205022 @default.
- W2914446712 creator A5050590989 @default.
- W2914446712 creator A5057063360 @default.
- W2914446712 creator A5065698591 @default.
- W2914446712 creator A5083967189 @default.
- W2914446712 date "2018-11-29" @default.
- W2914446712 modified "2023-09-26" @default.
- W2914446712 title "Epigenetic Therapy Targets Th1/Th17 Polarization to Reversing Immune Evasion and Treating Leukemia Relapse Post Allogeneic Stem Cell Transplantation in Non-APL AML Patients" @default.
- W2914446712 doi "https://doi.org/10.1182/blood-2018-99-111671" @default.
- W2914446712 hasPublicationYear "2018" @default.
- W2914446712 type Work @default.
- W2914446712 sameAs 2914446712 @default.
- W2914446712 citedByCount "0" @default.
- W2914446712 crossrefType "journal-article" @default.
- W2914446712 hasAuthorship W2914446712A5023205295 @default.
- W2914446712 hasAuthorship W2914446712A5030479246 @default.
- W2914446712 hasAuthorship W2914446712A5033694430 @default.
- W2914446712 hasAuthorship W2914446712A5040205022 @default.
- W2914446712 hasAuthorship W2914446712A5050590989 @default.
- W2914446712 hasAuthorship W2914446712A5057063360 @default.
- W2914446712 hasAuthorship W2914446712A5065698591 @default.
- W2914446712 hasAuthorship W2914446712A5083967189 @default.
- W2914446712 hasBestOaLocation W29144467121 @default.
- W2914446712 hasConcept C104317684 @default.
- W2914446712 hasConcept C126322002 @default.
- W2914446712 hasConcept C143998085 @default.
- W2914446712 hasConcept C150194340 @default.
- W2914446712 hasConcept C190727270 @default.
- W2914446712 hasConcept C203014093 @default.
- W2914446712 hasConcept C2778461978 @default.
- W2914446712 hasConcept C2779823535 @default.
- W2914446712 hasConcept C2780235182 @default.
- W2914446712 hasConcept C2780737395 @default.
- W2914446712 hasConcept C2781413609 @default.
- W2914446712 hasConcept C2911091166 @default.
- W2914446712 hasConcept C41091548 @default.
- W2914446712 hasConcept C55493867 @default.
- W2914446712 hasConcept C71924100 @default.
- W2914446712 hasConcept C86803240 @default.
- W2914446712 hasConceptScore W2914446712C104317684 @default.
- W2914446712 hasConceptScore W2914446712C126322002 @default.
- W2914446712 hasConceptScore W2914446712C143998085 @default.
- W2914446712 hasConceptScore W2914446712C150194340 @default.
- W2914446712 hasConceptScore W2914446712C190727270 @default.
- W2914446712 hasConceptScore W2914446712C203014093 @default.
- W2914446712 hasConceptScore W2914446712C2778461978 @default.
- W2914446712 hasConceptScore W2914446712C2779823535 @default.
- W2914446712 hasConceptScore W2914446712C2780235182 @default.
- W2914446712 hasConceptScore W2914446712C2780737395 @default.
- W2914446712 hasConceptScore W2914446712C2781413609 @default.
- W2914446712 hasConceptScore W2914446712C2911091166 @default.
- W2914446712 hasConceptScore W2914446712C41091548 @default.
- W2914446712 hasConceptScore W2914446712C55493867 @default.
- W2914446712 hasConceptScore W2914446712C71924100 @default.
- W2914446712 hasConceptScore W2914446712C86803240 @default.
- W2914446712 hasIssue "Supplement 1" @default.
- W2914446712 hasLocation W29144467121 @default.
- W2914446712 hasOpenAccess W2914446712 @default.
- W2914446712 hasPrimaryLocation W29144467121 @default.
- W2914446712 hasRelatedWork W2014904426 @default.
- W2914446712 hasRelatedWork W2084021611 @default.
- W2914446712 hasRelatedWork W2116269315 @default.
- W2914446712 hasRelatedWork W2120432903 @default.
- W2914446712 hasRelatedWork W2127522299 @default.
- W2914446712 hasRelatedWork W2144504798 @default.
- W2914446712 hasRelatedWork W2400187771 @default.
- W2914446712 hasRelatedWork W2899225691 @default.
- W2914446712 hasRelatedWork W2944780474 @default.
- W2914446712 hasRelatedWork W3081399433 @default.
- W2914446712 hasVolume "132" @default.
- W2914446712 isParatext "false" @default.
- W2914446712 isRetracted "false" @default.
- W2914446712 magId "2914446712" @default.
- W2914446712 workType "article" @default.